New daily pill could help millions shed pounds without diabetes

NCT ID NCT07081958

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 31 times

Summary

This study tests a new once-daily pill called RO7795081 for weight loss in adults with obesity or overweight who also have weight-related health problems like high blood pressure or sleep apnea. The trial involves 352 participants and lasts 38 weeks, comparing the drug to a placebo. The main goal is to see how much weight people lose after 30 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Accellacare - Hickory

Hickory, North Carolina, 28601, United States
Accellacare Research of Winston Salem

Winston-Salem, North Carolina, 27103, United States
Accellacare of Cary

Cary, North Carolina, 27518, United States
Accellacare of Duly Health and Care

Oak Lawn, Illinois, 60453, United States
Accellacare of Knoxville

Knoxville, Tennessee, 37912, United States
Accellacare of Piedmont Healthcare

Statesville, North Carolina, 28625, United States
Accellacare of Raleigh

Raleigh, North Carolina, 27609, United States
Accellacare of Rocky Mount

Rocky Mount, North Carolina, 27804, United States
Accellacare of Salisbury

Salisbury, North Carolina, 28144, United States
Accellacare of Wilmington, LLC

Wilmington, North Carolina, 28401, United States
Alliance for Multispecialty Research, LLC (AMR Norman)

Norman, Oklahoma, 73069, United States
Alliance for Multispecialty Research. LLC

Knoxville, Tennessee, 37909, United States
Apex Mobile Clinical Research

Bellaire, Texas, 77401, United States
Asclepes Research Centers

Sherman Oaks, California, 91403, United States
Chase Medical Research

Waterbury, Connecticut, 06708-3346, United States
Chrysalis Clinical Research

St. George, Utah, 84790, United States
Clinical Research Associates

Nashville, Tennessee, 37203, United States
Consano Clinical Research

Shavano Park, Texas, 78231, United States
Emerson Clinical Research Institute LLC

Washington D.C., District of Columbia, 20009, United States
Encompass Clinical Research

Spring Valley, California, 91978, United States
Internal Medicine and Pediatrics Associates of Bristol

Bristol, Tennessee, 37620, United States
Juno Research, LLC

Houston, Texas, 77040, United States
K2 Medical Research-Maitland

Maitland, Florida, 32751, United States
K2 Medical Research-Winter Garden

Clermont, Florida, 34711, United States
Knoxville-Summit-Halls Family Practice

Knoxville, Tennessee, 37938, United States
Manassas Clinical Research Center

Manassas, Virginia, 20110, United States
McFarland Clinic under Accellacare

Ames, Iowa, 50010, United States
Mercury Street Medical Group, PLLC

Butte, Montana, 59701, United States
Neurobehavioral Research, Inc.

Cedarhurst, New York, 11516, United States
Orange County Research Center

Lake Forest, California, 92630, United States
Pinnacle Research Group

Anniston, Alabama, 36207, United States
Prospective Research Innovations Inc.

Rancho Cucamonga, California, 91730, United States
Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, 30291, United States
Texas Diabetes & Endocrinology, P.A.

Austin, Texas, 78731, United States
Tristar Clinical Investigations

Philadelphia, Pennsylvania, 19114, United States
Velocity Clinical Research

Dallas, Texas, 75230, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RO7795081 (an oral drug for weight management)

What this could lead to

If successful, this could lead to a new once-daily pill to help people with obesity or overweight lose weight and improve related health conditions.

What could go wrong

This is an early Phase 2 trial, so the drug may not prove effective or safe enough for approval. Side effects and long-term risks are still unknown.

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OR OVERWEIGHT